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ArabianAbstract A sensitive, simple and rapid square-wave adsorptive stripping voltammetric method was
developed and validated for the determination of Ribavirin in pharmaceutical formulations. The
proposed method was based on the electrochemical reduction of Ribavirin at a hanging mercury
drop electrode in Britton Robinson buffer at pH 10. A well-deﬁned peak was observed at
880 mV with 30 s of accumulation time and 50 mV of accumulation potential. Under these opti-
mized conditions, the square-wave adsorptive stripping voltammetric peak current showed a linear
correlation on drug concentration over the range of 1 · 1010–2 · 107 mol L1 with a correlation
coefﬁcient of 0.9995 for the proposed method. The detection and quantitation limits for this method
were 2.02 · 1010 and 6.80 · 1010 mol L1, respectively. The results obtained for intra-day and
inter-day precision (as RSD %) were between 0.447% and 1.024%. This method was applied suc-
cessfully for the determination of Ribavirin in its pharmaceutical dosage forms with mean recover-
ies of 99.68 ± 0.13 with RSD % of 0.81% and 99.20 ± 0.24 with RSD % of 0.49% for two
concentrations 5 · 109 and 5 · 108 mol L1, respectively for 200 mg capsules. The results
obtained from the developed square-wave adsorptive stripping voltammetric method were com-
pared with those obtained by the analytical method reported in the literature.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Ribavirin (RBV), (1-b-D-ribofuranosyl-1,2,4-triazole-3-car-
boxamide, also known as virazole) (Fig. 1), is a synthetic pur-
ine nucleoside analog ﬁrst synthesized (Witkowski et al., 1972).2363011.
hoo.com (S.A. Ahmed).
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Journal of Chemistry (2013), http:/It was reported to have broad-spectrum activity against a vari-
ety of DNA and RNA viruses (Sidwell et al., 1972; Tam et al.,
2001). It has been used in treating respiratory syncytial virus
infections in seriously ill pediatric patients, and against inﬂu-
enza A and B virus and Lassa fever virus infections (Gilbert
and Knight, 1986) It has been found to be efﬁcacious also in
the treatment of hepatitis C virus (HCV) infections, in partic-
ular when combined with either interferon a-2a/2b or peginter-
feron a-2a/2b (Fried et al., 2002; Manns et al., 2001).
Studies of the therapeutic effect of the drug required the use
of sensitive methods for its determination at trace levels. Several
analytical methods for quantitating RBV have been developed;
these include bioassay (Smee et al., 1981), radioimmunoassaying Saud University.
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Figure 1 The structural formula of Ribavirin.
2 A.A. Abdel Gaber et al.(Austin et al., 1983), gas chromatography–mass spectrometry
(Roboz and Suzuki, 1978), capillary electrophoresis (CE)
(Breadmore et al., 2004.) and high performance liquid chroma-
tography (HPLC) with UV (Breadmore et al., 2004; Larra et al.,
2003; Granich et al., 1989; Svensson et al., 2000; Inoue et al.,
2004) or with mass spectrometric (MS) (D’Avolio et al., 2006;
Shou et al., 2002; Lin et al., 2002, Liu et al., 2006; Li et al.,
2007) detection. There is no information about the voltammetric
determination of RBV at a hanging mercury drop electrode
(HMDE) and its analytical applications in the literature.
This work aimed to develop a new square-wave adsorptive
stripping voltammetric (SWAdSV) method for the determina-
tion of RBV in bulk form, pharmaceutical formulations and
biological samples. Furthermore, the determination of RBV
using an electrochemical method, especially stripping analysis
was not studied before.
2. Experimental
2.1. Apparatus
Square-wave adsorptive stripping voltammetric studies were
carried out using AMEL 433 TRACE ANALYSER involving
a three-electrode system consisting of a hanging mercury drop-
ping electrode (HMDE) as a working electrode, an Ag/AgCl
with saturated KCl as a reference electrode and a platinum
wire as a counter electrode. A magnetic stirrer and stirring
bar provided the convective transport during pre-concentra-
tion. The peak heights were automatically or manually mea-
sured using the ‘tangent ﬁt’ capability of the instrument.
Cyclic voltammograms were recorded with the same instru-
ment (scan rate 50 mV s1). All measurements were performed
at room temperature (25 ± 1 C). The pH measurements were
made with Accumet model 825 pH meter.
2.2. Reagents and solutions
All chemicals used for the preparation of buffers and support-
ing electrolytes were of analytical grade (Merk or Sigma).
Bidistilled water was used throughout all experiments. Pure-
grade powder of RBV and the pharmaceutical product,
namely ‘‘Virin 200 mg’’ capsules were obtained from Sigma
Co., Cairo, Egypt. A stock solution of 1 · 103 mol L1
RBV was prepared by dissolving the required amount of this
drug in bidistilled water. Three different buffer solutions, Brit-
ton-Robinson (B.R.), ammonia/ammonium chloride and boric
acid/NaOH buffers were used.Please cite this article in press as: Abdel Gaber, A.A. et al., Cathodic adsorpt
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10 mL of the Britton-Robinson (B.R.) at pH 10 including
0.01 M KCl was taken to the electrochemical cell and the solu-
tion was purged with pure nitrogen for 15 min. The required
accumulation potential (Eacc. = 50 mV) was applied to the
working electrode for a selected accumulation time
(tacc. = 30 s), while the solution was stirred continuously at
400 rpm. The stirring was stopped and after equilibrium time
of 10 s, a negative-going potential scan was initiated using
the following parameters: frequency (f) = 100 Hz; pulse ampli-
tude (Esw) = 100 mV; scan increment (DE) = 10 mV. After
the voltammogram of supporting electrolyte had been re-
corded, aliquots of the RBV standard were introduced by
micropipette and the square-wave voltammetric cycles were re-
peated using a new mercury drop. The SWAdSV scan and cyc-
lic voltammetry were conducted from 600 to 1300 mV. All data
were obtained at room temperature.
2.4. Analytical applications
2.4.1. Assay of drug in capsule
The whole content of one capsule Virin (200 mg) was accu-
rately weighed; the required amount from the capsule powder
was transferred to a 100 mL volumetric ﬂask and dissolved in
bidistilled water. The solution was then ﬁltrated and the residue
was washed three times with water, the ﬂask was completed to
the mark with water. A suitable volume of the stock solution
was pipetted into a 10 mL-measuring ﬂask and the procedure
was repeated as described above. The nominal content of the
capsule was calculated using standard addition method.
2.4.2. Assay of drug in human urine
A urine sample (10 lL) taken from a healthy person was added
to the voltammetric cell containing 10 mL of Britton-Robin-
son B.R. buffer at pH 10 including 0.01 M KCl, i.e. the dilu-
tion factor of the urine sample in the cell was 1:1000. The
voltammogram was recorded, then 10 lL spikes of the stan-
dard solution of RBV were introduced into the cell and the
voltammograms were recorded after each addition.
2.4.3. Assay of drug in spiked human plasma
Serum samples were obtained from a healthy volunteer and
stored frozen until assay. After gently thawing, an aliquot vol-
ume of sample was fortiﬁed with RBV dissolved in bidistilled
water to achieve appropriate concentration. The solution was
centrifuged for 30 min at 3600 rpm to remove the precipitated
serum protein and the supernatant was taken carefully. Appro-
priate volume of the supernatant liquor was transferred to the
voltammetric cell.
3. Results and discussion
3.1. Square-wave stripping voltammetry
3.1.1. Effect of supporting electrolyte and pH
The voltammetric response of drugs is mainly dependent on
the pH of the buffer. Therefore, the electrochemical behavior
of RBV was evaluated over a pH range of 2.010 at HMDE
using the SWAdSV method. RBV exhibited a cathodic peakive stripping voltammetric determination of Ribavirin in pharmaceutical
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Figure 3 Effect of different buffers at pH = 10 on the SWAdCS
voltammetric peak current (ip), for 5 · 107 mol L1 RBV. The
other conditions were as those indicated in Fig. 2. (a) B.R., (b)
ammonia/ammonium chloride and (c) boric acid/NaOH buffers.
Cathodic adsorptive stripping voltammetric determination of Ribavirin in pharmaceutical dosage form, urine and serum 3in B.R. buffer over the pH range of 8.010 (Fig. 2). No peak
was observed at pH values 2.07.0. The response was examined
in the presence of other buffers, e.g. ammonia/ammonium
chloride and boric acid/NaOH. The best result with respect
to sensitivity (peak height), resolution (peak shape) and repro-
ducibility was recorded in B.R. buffer solution of pH 10.
Therefore, B.R. buffer at pH 10 was chosen as the supporting
electrolyte for the optimization of other variables and for anal-
ysis of RBV (Fig. 3).
The presence of KCl increases the ability of the analyte to
adsorb on the electrode surface (Ali, 1999). Therefore the opti-
mal conditions for studying the square-wave adsorptive strip-
ping voltammetry of RBV involve 0.04 M B.R. buffer at pH
10 including 0.01 M KCl.
3.1.2. Optimization of the operating parameters
The dependence of adsorptive stripping peak current of RBV
on the accumulation time tacc. was tested at four concentration
levels, 2 · 106, 2 · 107, 2 · 108 and 5 · 109 mol L1 RBV
from 10 to 60 s at Eacc. = 50 mV (Fig. 4). When the tacc. was
increased, a remarkable enhancement was observed for the
peak current of RBV up to 30 s and then the peak current lev-
eled off due to the saturation of the surface of the working
electrode by the analyte. For further experiments an accumu-
lation time of 30 s was selected as optimal because it provided
relatively high peak current with adequate practical time.
The inﬂuence of Eacc. on the stripping voltammetric signal
of 5 · 107 mol L1 RBV was examined over the range of 0
to 600 mV at constant tacc. = 30 s in stirred solution (Fig. 5).
The peak current increased steadily and reached its maximum
value at 50 mV and then decreased sharply. Hence,
Eacc. = 50 mV was chosen for optimal analytical sensitivity.
Study of the effect of scan increment (DE) on square-wave
stripping peak current of the drug in B.R. at pH 10 including
0.01 M KCl revealed that, the peak current enhanced on the
increase of scan increment (212 mV). A scan increment of
10 mV was preferable in the present study. At pulse ampli-
tude(Esw of 100 mV), the peak was found to be much more
sharp and deﬁned. Hence, Esw = 100 mV was chosen for the8.0 8.5 9.0 9.5 10.0
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Figure 2 Effect of pH of B.R. buffer on the SWAdCS
voltammetric peak current (ip), for 5 · 107 mol L1 RBV at
Eacc. = 50 mV, tacc. = 30 s, rest time = 10, scan increment
DE= 10 mV and pulse amplitude Esw = 100 mV.
Please cite this article in press as: Abdel Gaber, A.A. et al., Cathodic adsorpt
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100 mV pulse amplitude, wave period varied from 50 to
120 ms. The highest peak current was found at 100 ms, which
is used in the present study.
In order to obtain the maximum development of the
SWAdCS voltammetry peak current, optimization of such
variables was attempted. Frequency was found to be 100 Hz
using accumulation potential (Eacc.) = 50 mV, tacc. = 30 s,
scan increment (DE) = 10 mV, and pulse amplitude (Esw) of
100 mV.
3.2. Cyclic voltammetry
A cyclic voltammogram of 5 · 106 mol L1 RBV in 0.04 M
B.R. buffer at pH 10 including 0.01 M KCl was recorded. A
single cathodic peak, corresponding to the reduction of the10 20 30 40 50 60 70
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Figure 4 Effect of the accumulation timetacc. on the SWAdCS
voltammetry peak current (ip) for (a) 2 · 106 mol L1, (b)
2 · 107 mol L1, (c) 2 · 108 mol L1 and (d) 5 · 109 mol L1
RBV in B.R. buffer pH = 10 including 0.01 M KCl, and other
operational parameters were as those indicated in Fig. 2.
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Figure 5 Effect of the accumulation potentialEacc. on the
SWAdCS voltammetry peak current (ip) of 5 · 107 mol L1
RBV in B.R. buffer pH = 10 including 0.01 M KCl, and other
operational parameters were as those indicated in Fig. 2.
Figure 7 Repeatative cyclic voltammograms for
5 · 106 mol L1 RBV in B.R. buffer pH 10 including 0.01 M
KCl at scan rate 50 mV s1, equilibrium time = 15 s, (a) ﬁrst
cycle, (b) second cycle, (c) third cycle and (d) forth cycle.
4 A.A. Abdel Gaber et al.adsorbed drug, was observed at 880 mV. No peak was ob-
served in the anodic branch, indicating that RBV reduction
is an irreversible process and the desorption of the adsorbed
product, inhibits the appearance of the oxidation product. A
maximum developed peak current (ip) was achieved after accu-
mulation of the drug onto the electrode surface for 30 s; this
behavior conﬁrmed the adsorptive character of the drug at
the mercury surface.
The interfacial adsorptive character of RBV onto the
HMDE was identiﬁed from the peak current (ip) dependence
after preconcentration of the drug for 30 s upon the scan rate
m. The plot of log ip vs. log m (Fig. 6), gave a straight line over
the 20–200 mV s1 following the equation: Log ip (l
A) = 0.77 + 1.03 log m (mV s1) (r= 0.998). The slope value
of 1.03 is close to the theoretical value of 1.0 that is expected
for an ideal reaction of surface species (Laviron, 2002).2.0
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Figure 6 log m (scan rate) vs. log ip (peak current) for
5 · 106 mol L1, RBV in B.R. buffer pH 10 including 0.01 M
KCl and equilibrium time = 15 s and tacc. = 30 s.
Please cite this article in press as: Abdel Gaber, A.A. et al., Cathodic adsorpt
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peak current decreases sharply in the second and third cycles
indicating the rapid desorption of drug species out of the mer-
cury drop surface during the accumulation.
3.3. Validation of the proposed method
In the present work, quantiﬁcation of RBV was based on the
extend of the dependence of peak current upon its concentra-
tion in the analyzed solution under the optimal procedural
conditions. Validation of the proposed SWAdCS voltammetric
procedure for trace assay of RBV was examined via linearity
and sensitivity, repeatability and intermediate precision,
robustness, ruggedness, speciﬁcity and interference study.
3.3.1. Linearity and sensitivity of the proposed method
Calibration curves for RBV were attempted under the opti-
mized procedure conditions and followed different accumula-
tion time periods at 50 mV. The regression equation
associated with the calibration curves, (Table 1) exhibited a
good linearity that supported the proposed procedure. RBV
limit of detection (LOD) and limit of quantiﬁcation (LOQ)
of bulk RBV were estimated from the following equation:
LOD= 3.3 SDa/b LOQ= 10 SDa/b (where SDa is the
standard deviation of the intercept, and b is the slope of the
calibration graph). Both LOD and LOQ values in (Table 1)
conﬁrmed the sensitivity of the proposed method compared
with those that calculated by liquid chromatography tandem
mass spectrometry method.
3.3.2. Repeatability and intermediate precision
Repeatability and intermediate precision were examined by
performing six successive measurements for the different con-
centrations 5 · 107, 5 · 108 and 5 · 109 mol L1 of authen-
tic RBV demonstrated the reproducibility of the results
obtained by the proposed procedure. For intra-assay precision,
recoveries were calculated during one day and for inter-assay
precision, recoveries were calculated from the repeated analysis
for ﬁve days over a period of one week. The RSD values ofive stripping voltammetric determination of Ribavirin in pharmaceutical
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Table 1 Characteristic of the calibration plots of RBVa at Eacc. = 50 mV, rest time = 10 s, wave increment DE= 10 mV,
tacc. = 15 s, 30 s and wave amplitude Esw = 100 mV.
Parameter tacc. = 15 s tacc. = 30 s
Linearity range (M) 1 · 1010–2 · 107 1 · 1010–2 · 107
Regression equation (slope in lA/nM) ip = 61.9 + 39.7 c ip = 86.2 + 61.2 c
Correlation coeﬃcient (r) 0.9994 0.9995
Determination coeﬃcient (r2) 0.9988 0.9990
LOD (M) 2.24 · 1010 2.02 · 1010
LOQ(M) 6.13 · 1010 6.80 · 1010
a Average of three determinations.
Table 3 Inﬂuence of variation of some of the operational parameters of the proposed procedure on the mean percentage recovery of
5 · 107 mol L1 RBV.
Variables Conditions (%) R± S.D.a
Change in pH of the medium at pH= 11 tacc. = 30 s, Eacc. = 0.05 V and DE= 10 mV 99.92 ± 0.42
Accumulation time tacc. = 35 s pH= 10, Eacc. = 0.05 V and DE= 10 mV 100.62 ± 0.63
Accumulation potential Eacc. = 55 mV pH= 10, tacc. = 30 s, and DE= 10 mV 99.34 ± 0.93
Wave increment DE= 11 mV pH= 10, Eacc. = 0.05 V and tacc. = 30 s 100.5 ± 0.82
a Average of ﬁve determinations.
Table 2 Analytical precision and accuracy of the proposed SWAdCS voltammetric procedure for determination of RBVa in bulk
form at Eacc. = 50 mV, rest time = 10 s, wave increment DE= 10 mV, tacc. = 30 s and wave amplitude Esw = 100 mV.
Sample Added amount mol L1 Amount found mol L1 R % Precision (RSD %) Accuracy (bias %)
Intra-day precision 5 · 107 5.01 · 107 100.15 0.447 0.036
5 · 108 4.95 · 108 99.6 1.024 0.21
5 · 109 4.99 · 109 99.39 0.969 0.096
Inter-day precision 5 · 107 4.99 · 107 99.58 0.542 0.0173
5 · 108 4.89 · 108 99.32 0.893 0.155
5 · 109 4.94 · 109 99.11 0.793 0.128
a Average of ﬁve determinations.
Cathodic adsorptive stripping voltammetric determination of Ribavirin in pharmaceutical dosage form, urine and serum 5intra- and inter-day studies (Within and between days not
more than 0.21% at low and high concentrations) were illus-
trated in (Table 2). Accuracy of the result expressed as bias %:
[bias %= (measured concentration–concentration ta-
ken) · 100/(concentration taken)].
3.3.3. Robustness and ruggedness
The robustness of an analytical procedure is a measure of its
capacity to remain unaffected by small, but deliberate varia-
tions in procedural parameters and provides an indication of
its reliability during normal usage. The most important proce-
dure variables at pH (10–11) included 0.01 M KCl, accumula-
tion potential (Eacc.) (50 to 55 mV), accumulation time
(tacc.) (30 to 35 s) and a wave increment (DE) (10 to 11 mV).
The results shown in (Table 3) indicated that none of these
variables signiﬁcantly affects the recovery of RBV. This pro-
vided an indication of the reliability of the proposed procedure
for the assay of drug and it could be considered robust.
Ruggedness was examined by applying the developed pro-
cedure to assay of drug using potentiostat instruments (poten-
tiostats model 263 A (PAR) and AMEL-433A) under the same
optimized experimental conditions at different elapsed times.Please cite this article in press as: Abdel Gaber, A.A. et al., Cathodic adsorpt
dosage form, urine and serum. Arabian Journal of Chemistry (2013), http:/The results obtained due to lab-to-lab and even day-to-day
variations were found reproducible since there was no signiﬁ-
cant difference in the recovery or the standard deviation values
obtained.
3.3.4. Speciﬁcity and interference study
The speciﬁcity of the proposed method was evaluated in the ab-
sence and presence of some organic and inorganic species e.g.
starch, glucose, glycine, uric acid, sodium carbonate, ferric ni-
trate, magnesium perchlorate, and calcium nitrate as a common
interference in pharmaceutical preparations. Assay of
5 · 107 mol L1 RBV was examined by the additions of
1 · 106 mol L1 up to 1 · 105 mol L1 of (sodium carbonate,
starch, glucose and calcium ions 1 · 106 mol L1), Table 4
shows that there is no change in the peak current of the drug
was observed, this indicate that is no signiﬁcant interference.
Thus, the procedure was able to assay RBV in the presence of
interference and hence it can be considered speciﬁc. But by the
addition of ferric nitrate, magnesium perchlorate, glycine, uric
acid and calcium nitrate 1 · 105 mol L1, a change in the
peak current of this drug was observed. The inﬂuence of
commonly used excipients (magnesium stearate, lactose andive stripping voltammetric determination of Ribavirin in pharmaceutical
/dx.doi.org/10.1016/j.arabjc.2013.07.051
Table 4 Effect of interfering species on the SWAdCS
voltammetric determination of RBV (5 · 107 mol L1).
Interfering species Concentration (mol L1) (%) R± SDa
Sodium carbonate 1 · 105 99.55 ± 0.63
1 · 106 99.06 ± 0.23
Starch 1 · 105 100.11 ± 0.47
1 · 106 98.85 ± 0.75
Glucose 1 · 105 100.65 ± 1.09
1 · 106 99.85 ± 0.68
Calcium nitrate 1 · 106 99.7 ± 0.45
a Average of ﬁve determination.
Figure 8 SWAdCS voltammetry for RBV spiked with human
serum samples in B.R. buffer pH = 10 including 0.01 M KCl, at
Eacc. = 50 and other operational parameters were as those
indicated in Fig. 2. (a) sample, (b) s + 0.5 · 108 mol L1, (c)
s + 1.0 · 108 mol L1, (d) s + 1.5 · 108 mol L1, (e)
s + 2.0 · 108 mol L1, (f) s + 2.5 · 108 mol L1 RBV
authentic.
6 A.A. Abdel Gaber et al.microcrystalline cellulose) was investigated before the
determination of the drug in dosage forms. No interference
was observed with the proposed method (no change in the peak
current).
3.3.5. Assay of drug in a pharmaceutical
The proposed SWAdCS voltammetric procedure was success-
fully applied to the direct determination of RBV in capsule
pharmaceutical formulations and the validity was assessed by
applying the standard addition methods. On plotting of peak
height vs. concentration of RBV, a straight line is obtained
over a range of 1 · 109–7 · 108 mol L1 for Virin capsule.
The average percentage recovery was 99.68 ± 0.81 and
99.2 ± 0.49 for two concentrations 5 · 109 and
5 · 108 mol L1 respectively for 200 mg Virin capsules, (Ta-
ble 5). The obtained mean percentage recovery (R %) and the
relative standard deviation (RSD %) based on the average of
two replicate measurements were recorded.
The results were compared statistically with the reference
method (Chilukuri et al., 1998). The t- and F-values did not ex-
ceed the theoretical ones (Table 5), indicating no signiﬁcant
difference.
3.3.6. Assay of biological samples
3.3.6.1. Urine. RBV was successfully determined in spiked hu-
man urine samples by applying the optimized procedure with-
out any prior extraction steps. The peak current vs. drug
concentration for samples a and b, respectively was presented
by a straight line followed by the equation;
ip (lA) = 0.46 C(M/10
8) + 0.367, ip (lA) = 0.41 C(M/
108) + 3.35 with a correlation coefﬁcient of 0.9993 and
0.9998. The percentage recoveries of RBV, based on average
of ﬁve replicate measurements, were found to be
100.12 ± 0.358 and 100.16 ± 0.554 for the two samples (a
and b) (Table 5).Table 5 Recovery % results in dosage forms, urine and serum sam
Samples Added conc. (mol L1) Found conc. (m
Virin 200 mg 5 · 109 4.98 · 109
5 · 108 4.96 · 108
Urine samples 8 · 109 8.01 · 109
8 · 108 8.01 · 108
Serum samples 2 · 109 1.99 · 109
2.5 · 108 2.499 · 108
Recovery by the reference method, 99.6 ± 0.37 (n= 6).
Theoretical value:t = 2.26 at the 95% conﬁdence level. Theoretical value
a Average of ﬁve determinations ± standard deviation.
Please cite this article in press as: Abdel Gaber, A.A. et al., Cathodic adsorpt
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plied for the determination of RBV in protein free spiked hu-
man serum samples. No extraction steps other than the
centrifugal protein separation were required prior to the assay
of drug. The peak current vs. drug concentration for samples a
and b respectively was presented by straight line followed by
the equation;
ip(lA)= 1.25C(M/10
8) + 0.25, ip (lA)= 1.28C(M/10
8) +
2.55 with a correlation coefﬁcient of 0.9999 and 0.9988. The
percentage recoveries of RBV, based on average of ﬁve
replicate measurements, were found to be 99.9 ± 0.743 and
99.99 ± 0.498 for the two samples (a and b) (Table 5 and
Fig. 8).
4. Conclusion
A simple, fast, sensitive and precise SWAdSV method was
developed for the determination of RBV in pharmaceutical
formulations and biological samples. This method was based
on the reduction of RBV at HMDE.
The sensitivity of the method signiﬁcantly enhanced
adsorption of the drug on the electrode surface and afterples.
ol L1) Mean recoverya (R %) RSD %
99.68 ± 0.808, t= 0.204, F= 1.75 0.81
99.20 ± 0.489, t= 1.5 , F= 4.8 0.49
100.12 ± 0.358 0.358
100.16 ± 0.5549 0.554
99.9 ± 0.742 0.743
99.99 ± 0.498 0.498
F= 5.19 at the 95% conﬁdence level.
ive stripping voltammetric determination of Ribavirin in pharmaceutical
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Cathodic adsorptive stripping voltammetric determination of Ribavirin in pharmaceutical dosage form, urine and serum 7careful choice of the operating parameters; extremely low
LOD and LOQ values could be reached. The method is simpler
and requires less expensive equipment than other methods.
It was concluded that the proposed method could be suc-
cessfully and reliably applied to the analysis of RBV in bulk
form and pharmaceutical formulations.
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